A Precision Medicine Breakthrough for Addiction.
Adial Pharmaceuticals is pioneering genetically targeted therapies for Alcohol Use Disorder — a global health crisis affecting tens of millions of people with limited effective treatment options. By combining precision medicine, companion diagnostics, and targeted therapeutics, Adial is developing a new generation of addiction treatments designed to improve outcomes and expand access to care.
Millions Struggle With Addiction. Effective Treatments Remain Limited.
Alcohol Use Disorder (AUD) represents one of the largest unmet medical needs in modern healthcare. Despite its enormous societal and economic impact, most patients receive no treatment and existing therapies often fail to deliver consistent results. Excessive alcohol consumption contributes to more than 200 diseases and health conditions1 and is responsible for 5.3% of deaths worldwide1. The economic impact is staggering. Alcohol misuse costs the U.S. economy approximately $250 billion annually2, yet treatment adoption remains extremely low.
This enormous treatment gap represents both a major public health challenge and a significant pharmaceutical opportunity.
- World Health Organization, Global Status Report on Alcohol and Health.
- Centers for Disease Control and Prevention, "Excessive Drinking Costs U.S. $249 Billion."
Existing Therapies Leave Millions Without Effective Solutions.
Despite decades of development, currently available medications for Alcohol Use Disorder face major barriers that limit their effectiveness and adoption.
The majority of patients with Alcohol Use Disorder remain untreated.
Genetically Targeted Therapy Designed for Better Outcomes
Adial's lead investigational drug candidate, AD04, is a genetically targeted serotonin-3 receptor antagonist designed to treat Alcohol Use Disorder in patients with specific genetic markers. The therapy is paired with a proprietary genetic diagnostic test that identifies individuals most likely to respond to treatment.
Designed to Treat Alcohol Use Disorder More Effectively.
Adial's lead drug candidate AD04 is a genetically targeted therapy designed to treat Alcohol Use Disorder in patients with specific genetic markers. AD04 works by modulating serotonin pathways associated with addictive behaviors and alcohol consumption.
- check_circle Precision medicine approach with companion genetic test
- check_circle Once-daily oral therapy
- check_circle No abstinence requirement before treatment
- check_circle Strong safety and tolerability profile
- check_circle Designed specifically to reduce heavy drinking
This differentiated profile could position AD04 as a new standard of care for targeted AUD patients.
Promising Results in Genetically Identified Patient Groups.
Clinical analysis of AD04 has demonstrated meaningful improvements in targeted patient populations. In heavy drinkers with the AG+ genotype, AD04 significantly reduced heavy drinking days compared with placebo.3
These results demonstrate the potential for precision medicine to dramatically improve addiction treatment outcomes.
- Adial Pharmaceuticals, ONWARD pivotal Phase 3 clinical trial analysis. AD04 is an investigational drug candidate that has not been approved by the FDA or any other regulatory authority.
Addressing a Multi-Billion-Dollar Global Health Crisis
Addiction disorders represent one of the largest unmet needs in modern medicine. Alcohol Use Disorder alone represents a multi-billion-dollar global market with significant societal costs and limited effective treatment options. By combining precision medicine with scalable diagnostics, Adial aims to redefine how addiction disorders are treated.
- check_circle Alcohol Use Disorder affects millions globally
- check_circle Large global market opportunity for effective treatments
- check_circle Significant unmet need for targeted therapies
- check_circle Potential expansion into additional addiction-related disorders
Positioned for the Next Phase of Development.
Adial is entering an important phase of development as it prepares for pivotal clinical studies and potential regulatory pathways for AD04. Strategic initiatives are positioning the company for long-term growth and value creation.
Invest in the Future of Precision Addiction Treatment
Adial Pharmaceuticals is advancing a new paradigm in addiction therapy — combining genetics, targeted therapeutics, and precision medicine to improve outcomes for millions of patients worldwide. As the company advances toward pivotal clinical development, investors have the opportunity to participate in a potentially transformative healthcare innovation.